Cheryl Guttman Krader
Managing unhappy presbyopia patients
Managing unhappy presbyopia patients
Addressing patient dissatisfaction after presbyopia-correcting IOL surgery requires listening to understand the problem. Time and patient reassurance may be adequate for resolving some issues.
Managing residual astigmatism after toric IOL surgery
Residual astigmatism is not uncommon after toric IOL implantation. Depending on its cause and magnitude, lens reorientation may be a good solution.
Anatomic outcome more precise in defining DME treatment failure
The goal of treatment for diabetic macular edema is to maintain or improve vision, but improvement of edema is a better metric for determining whether the treatment is having a benefit or failing.
Investigational BCG-refractory NMIBC Tx shows promise
“rAd-IFNα gene therapy is a breakthrough opportunity for effective local management of BCG-unresponsive NMIBC,” says researcher Colin P. N. Dinney, MD.
Waterjet ablation confers advantages over TURP
Heat-free high-velocity waterjet ablation (Aquablation) for BPH performed with an image-guided robot-assisted platform (AquaBeam System) met its primary safety and efficacy endpoints in a phase III study.
Intraoperative OCT faces prime time, but added technology needed
Intraoperative optical coherence tomography (OCT) is becoming widely available, and its adoption is increasing, but improvements in the technology are needed to maximize its readiness for prime time, according to Justis P. Ehlers, MD.
Prostate Ca study reveals more evidence of racial disparity
Results of a study examining receipt of definitive therapy for intermediate/high-risk localized prostate cancer provide further evidence of racial disparity in prostate cancer favoring Caucasian men over African-American men.
Prostate MRI-Bx may ID partial gland ablation candidates
Information from magnetic resonance imaging and systematic biopsy may be used to identify candidates for partial gland ablation among men with recurrent localized prostate cancer after radiation therapy, researchers from Memorial Sloan Kettering Cancer Center reported at the AUA annual meeting in Boston.
Fusion Bx-guided HIFU shows promise in localized PCa
Early follow-up of men with localized prostate cancer treated with novel technology that integrates fusion biopsy findings to guide high-intensity focused ultrasound (HIFU [Focal One]) shows the technique has promise for minimizing post-treatment morbidity while providing good cancer control, Italian researchers reported at the AUA annual meeting in Boston.
Neuroprotective strategy primed for progress
Neuroprotective strategy primed for progress
Advancing methods for evaluating therapeutic response have fostered a new era in glaucoma neuroprotection in which promising candidates are already being investigated in clinical trials and others are poised to begin phase I testing, said Jeffrey L. Goldberg, MD, PhD.

Poll